These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29293235)

  • 21. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.
    Rassy EE; Assi T; Rizkallah J; Kattan J
    Immunotherapy; 2017 Mar; 9(4):309-311. PubMed ID: 28303768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody alarm call rouses immune response to cancer.
    Hayden EC
    Nature; 2012 Jun; 486(7401):16. PubMed ID: 22678259
    [No Abstract]   [Full Text] [Related]  

  • 24. Cocktails for cancer with a measure of immunotherapy.
    Ledford H
    Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
    [No Abstract]   [Full Text] [Related]  

  • 25. Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Oda K; Kato K; Nakamura M; Jotatsu T; Noguchi S; Kawanami T; Kido T; Yatera K
    Lung Cancer; 2018 Apr; 118():171-172. PubMed ID: 29496324
    [No Abstract]   [Full Text] [Related]  

  • 26. Releasing the Brakes on Cancer Immunotherapy.
    Ribas A
    N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216
    [No Abstract]   [Full Text] [Related]  

  • 27. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 29. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 30. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
    Cheah CY; Fowler NH; Neelapu SS
    Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
    [No Abstract]   [Full Text] [Related]  

  • 33. Beyond ipilimumab: new approaches target the immunological synapse.
    Garber K
    J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
    [No Abstract]   [Full Text] [Related]  

  • 34. [Regulatory T cells in cancer immunotherapy].
    Nishikawa H
    Rinsho Ketsueki; 2014 Oct; 55(10):2183-9. PubMed ID: 25297785
    [No Abstract]   [Full Text] [Related]  

  • 35. Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
    Ariyasu R; Horiike A; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Nishio M
    Anticancer Res; 2017 Aug; 37(8):4229-4232. PubMed ID: 28739711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
    Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
    Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Eltobgy M; Oweira H; Giryes A; Tekbas A; Decker M
    Immunotherapy; 2017 Nov; 9(14):1175-1183. PubMed ID: 29067884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Otelixizumab in the treatment of type 1 diabetes mellitus.
    Sprangers B; Van der Schueren B; Gillard P; Mathieu C
    Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.